Meier F, Nesbit, M, Hsu M-Y, Martin, B,
Van Belle P, Elder, DE, Schaumburg-Lever,
G, Garbe, C, Walz, TM, Crombleholme T, Herlyn
M: Human melanoma progression in skin reconstructs:
Biological significance of bFGF. Am. J.
Pathol. 156: 193-200, 2000. PDF
version available
Sylvester KG, Crombleholme TM, Radu
A, Nesbit M, Herlyn M, Adzick NS: Gene therapy
in wound healing: Acute inflammatory response
to adenovirus and transgene in human skin.
Wound Healing Regen.: 8, 36-44. 2000. PDF
version available
St. John , L, Sauter, ER, Herlyn, M,
Litwin, SA, Adler-Storthz, K: Endogenous
p53 gene status predicts the response of
human squamous cell carcinomas to wild-type
p53. Cancer Gene Therapy, 7: 749-756, 2000.
PDF
version available
Hsu, M-Y, Meier, F, Nesbit, M, Hsu, J-Y,
Herlyn, M: E-cadherin expression in melanoma
cells restores keratinocyte-mediated growth
control and down-regulates expression of
invasion-related adhesion receptors. Am.
J. Pathol, 156: 1515-1525, 2000. PDF
version available
Sauter, ER, Herlyn, M, Liu, S-C, Litwin,
S, Ridge, JA: Prolonged response to antisense
cyclin D1 in a human squamous cancer xenograft
model. Clin Cancer Res, 6:654-660, 2000.
PDF
verson available
Hsu, M-Y, Andl, T, Li, G, Meinkoth, JL,
Herlyn, M: Cadherin repertoire determines
partner-specific gap junctional communication
during melanoma progression. J. Cell Sci,
113: 1535-1542, 2000.
PDF
version available
Satyamoorthy, K, Oka , M, Herlyn, M:
An antisense strategy for inhibition of
human melanoma growth targets the growth
factor pleiotrophin. Pigm. Cell Res. 13
(Suppl. 8), 87-93, 2000. PDF
version available
Fredericks , WJ, Ayyanatham, K, Herlyn,
M, Friedman, JR, Rauscher, FJ,III: An engeneered
PAX3-KRAB transcriptional repressor inhibits
the malignant phenotype of alveolar rhabdomyosarcoma
cells harboring the endogenous PAX3-FKHR
oncogene. Molec Cell Biol, 20: 5019-5031,
2000. PDF
version available
Smedley, D., Sidar, S, Birdsall, S, Bennet,
D, Herlyn, M, Cooper, C, Shipley, J: Characterization
of chromosome 1 abnormalities in malignant
melanomas. Gene Chromosome Cancer, 28: 121-125,
2000. PDF
version available
Satyamoorthy, K, Chehab , NH , Waterman,
MJF, Lien, MC, El-Deiry, W, Herlyn, M, Halazonetis,
TD: Aberrant regulation and function of
wild-type p53 in radioresistant melanoma
cells. Cell Growth & Differentiation,
11: 467-474, 2000. PDF
version available
Chandler, LA, Doukas, J, Gonzalez, AM,
Hoganson, DK, Gu, D, Ma, C, Nesbit, M, Crombleholme,
TM, Herlyn, M, Sosnowski, BA, Pierce, GF:
FGF2-Targeted adenovirus encoding platelet-derived
growth factor-B enhances de novo tissue
formation. Molec. Therapy, 2: 153-160, 2000.
PDF
version available
Ayyanathan, K, Fredericks , WJ, Berking,
C, Herlyn, M, Balakrishnan, C, Gunther,
E, Rauscher, FJ, III: Hormone-dependent
tumor regression in vivo by an inducible
transcriptional repressor directed at the
PAX3-FKHR oncogene. Cancer Res, 60: 5803-5814,
2000. PDF
version available
Li, G, Herlyn, M: Dynamics of intercellular
communication during melanoma development.
Molecular Med. Today 6: 163-169, 2000. (R) PDF
version available
Herlyn, M, Berking, C, Li, G, Satyamoorthy,
K: Lessons from melanocyte development for
naevus and melanoma formation. Mel. Res.10:
303-312, 2000. (R) PDF
ver sion available
Cascinelli, N, Herlyn, M, Schneeberger,
A, Kuwert, C, Slominski, A, Armstrong, C,
Belli, F, Lukiewcz, S, Maurer, D, Ansel,
J, Stingl, G, Saida, T: What is the most
promising strategy for the treatment of
metastasizing melanoma? Exp. Dermatol. 9:
439-451, 2000. (R) PDF
version available
Herlyn, M, Satyamoorthy, K: Molecular biology
of cutaneous melanoma. In: 6th edition of
Cancer: Principles and Practice of Oncology,
ed. By DeVita, Jr, VT, Hellman, S, Rosenberg,
SA, Lippincott Williams &Wilkins, Philadelphia
, PA , pp. 2003-2012, Chap. 42, 2000. PDF
version available
Margolis, DJ, Crombleholme, TM, Herlyn,
M: Clinical protocol: Phase I trial to evaluate
the safety of H5.020CMV.PDGF-B for the treatment
of a diabetic insensate foot ulcer. Wound
Rep. Regen., 8: 480-493, 2000. PDF
version available